Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Eloy E. Ordaya; Elena Beam; Joseph D. Yao; Raymund R. Razonable; Paschalis Vergidis

doi:10.1093/ofid/ofac283

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Eloy E. Ordaya, Elena Beam, Joseph D. Yao, Raymund R. Razonable, Paschalis Vergidis

Infectious Diseases

Research output: Contribution to journal › Article › peer-review

Abstract

Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.

Original language	English (US)
Article number	ofac283
Journal	Open Forum Infectious Diseases
Volume	9
Issue number	7
DOIs	https://doi.org/10.1093/ofid/ofac283
State	Published - Jul 1 2022

Keywords

COVID-19
immunocompromised hosts
monoclonal antibodies
transplant infectious diseases

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofac283

Cite this

@article{4638e9b7473a405d944bfad21e37f509,

title = "Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis",

abstract = "Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.",

keywords = "COVID-19, immunocompromised hosts, monoclonal antibodies, transplant infectious diseases",

author = "Ordaya, {Eloy E.} and Elena Beam and Yao, {Joseph D.} and Razonable, {Raymund R.} and Paschalis Vergidis",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press on behalf of the Infectious Diseases Society of America.",

year = "2022",

month = jul,

day = "1",

doi = "10.1093/ofid/ofac283",

language = "English (US)",

volume = "9",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

AU - Ordaya, Eloy E.

AU - Beam, Elena

AU - Yao, Joseph D.

AU - Razonable, Raymund R.

AU - Vergidis, Paschalis

PY - 2022/7/1

Y1 - 2022/7/1

N2 - Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.

AB - Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.

KW - COVID-19

KW - immunocompromised hosts

KW - monoclonal antibodies

KW - transplant infectious diseases

UR - http://www.scopus.com/inward/record.url?scp=85136294575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136294575&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofac283

DO - 10.1093/ofid/ofac283

M3 - Article

AN - SCOPUS:85136294575

SN - 2328-8957

VL - 9

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 7

M1 - ofac283

ER -

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this